Nothing Special   »   [go: up one dir, main page]

Chapgier et al., 2009 - Google Patents

A partial form of recessive STAT1 deficiency in humans

Chapgier et al., 2009

View HTML
Document ID
11822712314346497413
Author
Chapgier A
Kong X
Boisson-Dupuis S
Jouanguy E
Averbuch D
Feinberg J
Zhang S
Bustamante J
Vogt G
Lejeune J
Mayola E
De Beaucoudrey L
Abel L
Engelhard D
Casanova J
et al.
Publication year
Publication venue
The Journal of clinical investigation

External Links

Snippet

Complete STAT1 deficiency is an autosomal recessive primary immunodeficiency caused by null mutations that abolish STAT1-dependent cellular responses to both IFN-α/β and IFN-γ. Affected children suffer from lethal intracellular bacterial and viral diseases. Here we report a …
Continue reading at www.jci.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Similar Documents

Publication Publication Date Title
Chapgier et al. A partial form of recessive STAT1 deficiency in humans
Bastard et al. Herpes simplex encephalitis in a patient with a distinctive form of inherited IFNAR1 deficiency
Rackov et al. p21 mediates macrophage reprogramming through regulation of p50-p50 NF-κB and IFN-β
Bengtsson et al. Role of interferons in SLE
Sarkar et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa
Wang et al. Inhibition of AIM 2 inflammasome activation by a novel transcript isoform of IFI 16
Muskardin et al. Type I interferon in rheumatic diseases
Lévy et al. Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency
Brehm et al. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production
Sancho-Shimizu et al. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency
Dupuis et al. Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency
Yan et al. IRF3 reduces adipose thermogenesis via ISG15-mediated reprogramming of glycolysis
Keskitalo et al. Novel TMEM173 mutation and the role of disease modifying alleles
Davidson et al. An update on autoinflammatory diseases: interferonopathies
Kong et al. A novel form of human STAT1 deficiency impairing early but not late responses to interferons
Rönnblom The type I interferon system in the etiopathogenesis of autoimmune diseases
Miceli‐Richard et al. The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren's syndrome
Liang et al. Reduced transcriptional activity in individuals with IL-18 gene variants detected from functional but not association study
Tsumura et al. Dominant‐negative STAT1 SH2 domain mutations in unrelated patients with Mendelian susceptibility to mycobacterial disease
Stone et al. Interferon regulatory factor 5 activation in monocytes of systemic lupus erythematosus patients is triggered by circulating autoantigens independent of type I interferons
Saigusa et al. Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis
Hirata et al. Heterozygosity for the Y701C STAT1 mutation in a multiplex kindred with multifocal osteomyelitis
Chang et al. Genetic variants of PPAR-gamma coactivator 1B augment NLRP3-mediated inflammation in gouty arthritis
Nihira et al. Detailed analysis of Japanese patients with adenosine deaminase 2 deficiency reveals characteristic elevation of type II interferon signature and STAT1 hyperactivation
Gothe et al. Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency